Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sorbitol + tislelizumab + oxaliplatin + S-1
- Development stage
- Unknown
- Lead developer
- BeiGene
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
sorbitol + tislelizumab + oxaliplatin + S-1 is an experimental combination regimen being evaluated for the neoadjuvant treatment of locally advanced gastric cancer and gastroesophageal junction adenocarcinoma. The regimen combines the PD-1 inhibitor tislelizumab with the SOX chemotherapy backbone (comprising the oral fluoropyrimidine S-1 and intravenous oxaliplatin) and oral sorbitol. Sorbitol is included as a metabolic modulator intended to enhance the efficacy of the chemo-immunotherapy combination. Tislelizumab is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, thereby restoring T-cell mediated anti-tumor activity. The SOX regimen is a standard-of-care chemotherapy in East Asian populations, providing cytotoxic effects through DNA cross-linking and inhibition of thymidylate synthase.
- Brand names
- TevimbraTS-1TS1TS 1Eloxatin
- Other names
- sorbitol + PD-1 inhibitor + SOX chemotherapySorbitol + Tislelizumab + SOXSorbitol + Tirellizumab + SOX
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)DPYD (Dihydropyrimidine dehydrogenase)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on sorbitol + tislelizumab + oxaliplatin + S-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sorbitol + tislelizumab + oxaliplatin + S-1.